Abvance Therapeutics
Edward Raskin is an accomplished professional with extensive experience in leadership and legal roles across various companies. Currently serving as Managing Director and Senior Consultant at LS Associates since August 2021, Raskin also holds the position of General Counsel and Corporate Strategy at Abvance Therapeutics since September 2023. Previous significant roles include Chief Executive Officer at Thermalin Inc. and Co-Founder and Board Member at Beta Bionics. Raskin's legal expertise was honed as Founding Partner at Kassinove & Raskin LLP and as an Attorney at Paul Hastings. Raskin's educational background includes a Corporate Director Certificate from Harvard Business School and a BA in Political Science from UC Irvine, with additional legal studies at the University of California, Berkeley - School of Law.
This person is not in any teams
This person is not in any offices
Abvance Therapeutics
Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities). Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management. ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.